Core Viewpoint - Quantum BioPharma Ltd. has announced an at-the-market offering of Class B Subordinate Voting Shares with an aggregate offering price of up to US$21,225,000 to fund clinical studies, research and development, and general corporate purposes [1][3]. Group 1: Offering Details - The Class B Shares will be sold through H.C. Wainwright & Co., LLC as the sales agent, with a cash commission of 3.0% on the gross proceeds raised [1][3]. - Sales will occur at prevailing market prices on the Nasdaq Stock Market, and no shares will be sold on the Canadian Securities Exchange or other Canadian markets [2][3]. Group 2: Use of Proceeds - The net proceeds from the ATM Offering are intended to fund various clinical studies, trials, and development programs, as well as research and development activities [3]. Group 3: Regulatory Compliance - The ATM Offering is being conducted under a registration statement filed with the SEC, which was declared effective on January 4, 2024 [4].

Core Viewpoint - Quantum BioPharma Ltd. has successfully dismissed a reconsideration motion by Dr. Raza Bokhari, affirming the company's position in a legal dispute regarding his termination as CEO [1][2]. Legal Proceedings - Dr. Raza Bokhari's claim of wrongful dismissal was dismissed by Arbitrator Cunningham, resulting in Quantum BioPharma being awarded approximately CAD $2.81 million in arbitration costs plus interest [2]. - The Court of Appeal awarded an additional CAD $180,000 in costs related to Dr. Bokhari's failed motion for leave to appeal [2]. - Quantum BioPharma has initiated a Petition to Confirm Arbitration Award in the U.S. District Court to collect the awarded amounts from Dr. Bokhari, which includes various monetary judgments totaling USD $147,301.04 and CAD $2,814,229.15, among others [3]. Company Overview - Quantum BioPharma is focused on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders [4]. - The company is advancing its lead compound, Lucid-MS, which aims to prevent and reverse myelin degradation associated with multiple sclerosis [4]. - Quantum BioPharma retains a 25.71% ownership stake in Celly Nutrition Corp., which markets the product UNBUZZD™, and is entitled to a 7% royalty on sales until reaching CAD $250 million, after which the royalty rate will decrease to 3% [4].

Core Viewpoint - Quantum BioPharma Ltd. has entered into a joint clinical study with Massachusetts General Hospital to validate a novel PET imaging technique for monitoring myelin integrity in multiple sclerosis patients [1][2]. Group 1: Clinical Study Details - The clinical study is titled "Preliminary Evaluation of [18F]3F4AP PET as a potential tool to monitor non-immunomodulatory drugs in multiple sclerosis" and is led by Dr. Pedro Brugarolas from MGH [2]. - The study will involve serial [18F]3F4AP PET scans alongside MRI scans in patients with both progressive and relapsing-remitting forms of MS [2]. - Previous studies indicated that [18F]3F4AP is highly sensitive to demyelinated lesions, suggesting its potential as a biomarker for monitoring demyelination changes in response to treatments [2]. Group 2: Company Insights - Quantum BioPharma is focused on developing innovative biopharmaceutical solutions for neurodegenerative disorders, with its lead compound, Lucid-MS, aimed at preventing and reversing myelin degradation [4]. - The company retains a 25.71% ownership stake in Celly Nutrition, which is involved in the development of the UNBUZZD™ product, and will receive a 7% royalty on sales until total payments reach $250 million, after which the royalty will drop to 3% [4]. - The collaboration with MGH is seen as relevant to the Lucid-MS clinical development program, which aims to protect the myelin sheath in MS [3].

Group 1 - Quantum BioPharma Ltd. has closed the final tranche of its offering, raising a total of $5 million to advance research and development of innovative drug candidates and for general working capital purposes [1][2] - The company has developed a formulation for rekvry™, aimed at treating alcohol misuse in emergency and hospital settings, addressing an unmet need in healthcare [2] - Quantum BioPharma is focused on neurodegenerative and metabolic disorders, with its lead compound, Lucid-MS, showing promise in preventing and reversing myelin degradation in preclinical models [3] Group 2 - The company retains a 25.71% ownership stake in Celly Nutrition, which markets the product UNBUZZD™, and is entitled to a 7% royalty on sales until reaching $250 million, after which the royalty will drop to 3% [3] - Quantum BioPharma maintains a portfolio of strategic investments through its subsidiary, FSD Strategic Investments Inc., which includes loans secured by residential or commercial property [3]